• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Haemonetics Corporation

    6/12/25 4:51:50 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001420910
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    HAEMONETICS CORP
    SEC File Number
    001-14041
    Address of Issuer
    125 SUMMER STREET
    BOSTON
    MASSACHUSETTS
    02110
    Phone
    7818487100
    Name of Person for Whose Account the Securities are To Be Sold
    Strong Stewart W
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Former Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    70850593.474803699606/12/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/12/2025Option Granted 05/16/2022IssuerCheckbox not checked35406/12/2025Cash
    Common06/12/2025Option Granted 05/18/2021IssuerCheckbox not checked35406/12/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Stewart Strong
    125 Summer Street
    Boston � MA � 02110
    Common06/02/20252835191277.45
    Stewart Strong
    125 Summer Street
    Boston � MA � 02110
    Common06/04/20257705538579.50

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/12/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Stewart Strong

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $HAE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    8/8/2025$62.00Overweight → Neutral
    Analyst
    8/8/2025$95.00 → $86.00Outperform
    Barrington Research
    7/9/2025$90.00Neutral → Buy
    Citigroup
    6/26/2025$87.00Outperform
    Robert W. Baird
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics downgraded by Raymond James with a new price target

    Raymond James downgraded Haemonetics from Strong Buy to Outperform and set a new price target of $78.00

    8/11/25 9:46:26 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics downgraded by Analyst with a new price target

    Analyst downgraded Haemonetics from Overweight to Neutral and set a new price target of $62.00

    8/8/25 8:19:52 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $86.00 from $95.00 previously

    8/8/25 7:34:13 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $HAE
    SEC Filings

    View All

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

    Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures. The submission builds upon the successful results of the PATCH study as well as positive clinical use in Europe, reinforcing the system's potential safety and performance profile. In addition, the company received European CE mark approval for an expanded indication for PerQseal Elite

    6/24/25 8:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    SEC Form 10-Q filed by Haemonetics Corporation

    10-Q - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:08:06 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:04:03 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    7/25/25 4:16:54 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Zane Ellen M was granted 2,693 shares, increasing direct ownership by 16% to 19,373 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:36:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Pomeroy Claire was granted 2,693 shares, increasing direct ownership by 19% to 16,872 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:33:39 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Kroll Mark W was granted 2,693 shares, increasing direct ownership by 13% to 23,357 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:30:46 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

    BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

    10/4/22 6:51:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Financials

    Live finance-specific insights

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

    5/8/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/12/24 12:54:20 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/8/24 10:41:07 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care